Chronic obstructive pulmonary disease patients with type 2 inflammation saw rapid and sustained improvements in their disease after treatment with the monoclonal antibody dupilumab.

Description of this mechanism offers a promising therapeutic target to limit lung injury and death. Lower respiratory tract infections, including bacterial pneumonia, are the fourth-leading cause of death worldwide, with 120 million to 156 million cases and 1.4 million deaths a year.

Having a bacterial infection at the same time as COVID-19 is a greater risk factor for COVID-19 severity and mortality than previously described risk factors such as advanced age, male sex or various comorbidities.

Sarcoidosis is an inflammatory disease characterized by the formation of granulomas in one or more organs of the body.

New screening guidelines and improvements in diagnostics and treatment have improved outcomes in lung cancer.

Women who have never smoked have smaller lung airways than men do, leading to higher risk for COPD.

U.S. News & World report named UAB Hospital as the best hospital in Alabama.

Record $95 million Heersink lead gift to advance strategic growth and biomedical innovation.

A Bcl-2 inhibitor that has FDA approval for treatment of several leukemias reversed lung fibrosis in a bleomycin mouse model.

Hamm was on ECMO for 147 days, a remarkably long time.

A new multidisciplinary program within UAB Medicine will help evaluate patients who have recovered from COVID-19 but are still experiencing symptoms and link them to the specialized care they need.

Alabama is one of 10 U.S. states with the highest rates of short sleep duration.

This study was done in mice and with a novel, tissue-engineered, three-dimensional breast cancer mimetic system.

This study included preclinical experiments and use of bronchoalveolar cells from IPF patients.

Airway fractal dimension gives added prognostic information over traditional CT scan measures in COPD.

With one in four high school students’ using e-cigarettes, UAB experts want parents to be aware of vaping’s harmful effects.

A diabetes drug suggests potential therapy for idiopathic pulmonary fibrosis, based on research with human lung fibroblasts and a mouse model of lung fibrosis.